IQ EQ FUND MANAGEMENT IRELAND Ltd Cuts Holdings in Stryker Co. (NYSE:SYK)

IQ EQ FUND MANAGEMENT IRELAND Ltd lessened its stake in Stryker Co. (NYSE:SYK - Free Report) by 16.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 17,714 shares of the medical technology company's stock after selling 3,600 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd's holdings in Stryker were worth $6,378,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Kohmann Bosshard Financial Services LLC bought a new position in Stryker in the 4th quarter worth $25,000. Dunhill Financial LLC raised its stake in shares of Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company's stock worth $27,000 after buying an additional 37 shares during the period. Rakuten Securities Inc. lifted its position in shares of Stryker by 618.2% during the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock valued at $28,000 after buying an additional 68 shares in the last quarter. Centricity Wealth Management LLC bought a new position in shares of Stryker during the 4th quarter valued at approximately $30,000. Finally, BankPlus Trust Department purchased a new stake in Stryker in the 4th quarter worth approximately $33,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Allan C. Golston sold 2,458 shares of Stryker stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.90% of the company's stock.

Remove Ads

Stryker Trading Down 0.9 %

Shares of SYK stock traded down $3.16 during trading hours on Friday, reaching $364.38. 1,274,307 shares of the stock were exchanged, compared to its average volume of 1,289,456. The firm has a market capitalization of $139.08 billion, a price-to-earnings ratio of 46.96, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The company's 50-day moving average price is $384.08 and its 200-day moving average price is $374.32. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59.

Stryker (NYSE:SYK - Get Free Report) last announced its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the firm earned $3.46 earnings per share. As a group, equities analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.92%. Stryker's dividend payout ratio (DPR) is 43.30%.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. JPMorgan Chase & Co. lifted their price target on shares of Stryker from $420.00 to $445.00 and gave the company an "overweight" rating in a report on Wednesday, January 29th. StockNews.com cut shares of Stryker from a "buy" rating to a "hold" rating in a research note on Thursday, March 6th. Citigroup reiterated a "buy" rating and issued a $450.00 price target on shares of Stryker in a research note on Wednesday, February 26th. Royal Bank of Canada boosted their price objective on Stryker from $425.00 to $435.00 and gave the company an "outperform" rating in a research report on Wednesday, January 29th. Finally, JMP Securities reissued a "market perform" rating on shares of Stryker in a research note on Tuesday, February 18th. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $421.90.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.